ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / URGN / insiders
CMPS (40) NBTX (49) MLYS (33) RARE (23) ⌘ Pro Terminal β†’

UroGen Pharma Ltd. (URGN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$34.36 +5.01% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $34.60

UroGen Pharma Ltd. (URGN) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $1.60B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on URGN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is URGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, UroGen Pharma Ltd. (NASDAQ: URGN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $34.36 (+5.01% 1D, market cap $1.60B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, URGN ranks #935 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does URGN compare to CMPS and NBTX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), URGN carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 88.7%, and ROIC of -35.0%. By comparison, CMPS (COMPASS Pathways Plc American Depository Shares) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B) and NBTX (Nanobiotix S.A.) posts a D grade (49/100 RQD, P/E N/A, ROIC β€”, cap $1.59B). Among the 5-stock peer group, URGN leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for URGN?
β–Ό

Per URGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001668243), UroGen Pharma Ltd. generated $109.8M in revenue (+21.4% YoY), -$153.5M in net income, and -$162.7M in free cash flow against $200.5M in total assets and $122.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $34.60 (+0.71%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (24/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510024
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk E
Cash (3)Whales (7)SEC (5)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15.3% Base Target
$53 Bull$29 Base$23 Bear
πŸ“¬ FREE URGN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for URGN)Realized 20D OHLCV Swing Band: Β±10.7%
Deterministic 5-Pillar Attribution (24/100 Composite)
πŸ” WHY URGN SCORES 24/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+8/20 pts (33% of score)

FRED Regime Γ— Technicals: 52% of 52W Range β€’ RSI-14 at 29.7 (OVERSOLD (<32))

β–² #2 Bullish Driver: Whale & Options Positioning+7/20 pts (29% of score)

20D Institutional Volume Accumulation (Β±10.7% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
32
Grade E$38.26-8.5% Next Q
Q2 (-2Q)
29
Grade E$35.01-3.1% Next Q
Q3 (-1Q)
27
Grade E$33.91+1.3% Next Q
Current
24
Grade E$34.36-10.9% Hist 90D Ξ±
Trajectory: E (32) β†’ E (24)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a URGN Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While URGN currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($39.90) and Max Pain ($36.08) forces dealer call-delta covering toward $53.35.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $URGNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œURGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 24%NO 76%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

URGN Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (URGN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on URGN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring URGN)

  • βœ“Walkthrough of URGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
URGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.53%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $33.48H $34.36L $32.72C $34.36VOL 1.17M
RES: $61.75SUP: $32.25SMA50: $39.90SMA200: $31.45
$52.94$44.13$35.32$26.51$17.71RES $61.75SUP $32.25$34.362026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

URGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ URGN Butterfly Map β†’ + Track URGN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +21.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on URGN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for URGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for URGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (URGN)

Health Care Rank #935 of 1015 βš”οΈ CMPS vs URGN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (URGN vs. CMPS, NBTX, MLYS, RARE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, UroGen Pharma Ltd. (URGN) ranks #935 by composite RQD confidence (24/100, grade E) and #291 by equity capitalization ($1.60B). Within this direct 5-issuer industry benchmark cohort, URGN leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and β€” gross margin. NBTX currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with URGN at 24/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
URGN ACTIVE
UroGen Pharma Ltd.
E 24/100 β€” 88.7% -35.0% +5.01% $1.60B Benchmark Subject
CMPS
COMPASS Pathways Plc American Depository Shares
D- 40/100 β€” β€” -35.0% -27.31% $1.60B /cmps-vs-urgn β†’
NBTX
Nanobiotix S.A.
D 49/100 β€” β€” β€” -10.39% $1.59B /nbtx-vs-urgn β†’
MLYS
Mineralys Therapeutics Inc.
E 33/100 β€” β€” -28.4% -14.47% $1.61B /mlys-vs-urgn β†’
RARE
Ultragenyx Pharmaceutical Inc.
E 23/100 β€” β€” -35.0% +1.24% $1.59B /rare-vs-urgn β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001668243 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), UroGen Pharma Ltd. (URGN) reported GAAP revenue of $109.8M (+21.4% vs. FY2024 revenue of $90.4M , and +32.7% cumulative change since FY2023) , GAAP net income of -$153.5M, operating cash flow of -$162.4M, and free cash flow of -$162.7M (-67.7% YoY). On the balance sheet, URGN closed FY2025 with $200.5M in total assets against $122.2M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $109.8M -$153.5M -$162.4M -$162.7M $200.5M $122.2M
FY2024 (FY) 2024-12-31 $90.4M -$126.9M -$96.8M -$97.1M $285.7M $121.7M
FY2023 (FY) 2023-12-31 $82.7M -$102.2M -$76.4M -$76.4M β€” β€”

3. URGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is URGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, UroGen Pharma Ltd. (NASDAQ: URGN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $34.36 (+5.01% 1D, market cap $1.60B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, URGN ranks #935 in composite RQD confidence.

How does URGN compare to CMPS and NBTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), URGN carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 88.7%, and ROIC of -35.0%. By comparison, CMPS (COMPASS Pathways Plc American Depository Shares) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B) and NBTX (Nanobiotix S.A.) posts a D grade (49/100 RQD, P/E N/A, ROIC β€”, cap $1.59B). Among the 5-stock peer group, URGN leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for URGN?

Per URGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001668243), UroGen Pharma Ltd. generated $109.8M in revenue (+21.4% YoY), -$153.5M in net income, and -$162.7M in free cash flow against $200.5M in total assets and $122.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is URGN trading relative to its 50-day, 200-day, and 52-week technical levels?

URGN last traded at $34.36 (+5.01% on volume of 2,039,058 shares), positioning the stock -13.88% below its 50-day simple moving average ($39.90) and +9.25% above its 200-day simple moving average ($31.45). Across its 52-week range of $16.50 to $50.81, URGN sits at the 52.1% percentile with a 14-day RSI of 29.7 (OVERSOLD (<32)) and an implied next-earnings move of Β±10.7% ($30.68 to $38.04).

Direct Sub-Reports: URGN RQD Cockpit URGN 12M Forecast URGN Earnings & Move URGN Dividends & DRIP URGN Insiders & 13F URGN Whale Options URGN Profit Sankey URGN News & Why
ROARABLE RATING BRIEF β€’ RQD 24/100 (E) βœ“ SEC XBRL & RQD VERIFIED

URGN β€” UroGen Pharma Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

UroGen Pharma Ltd. (URGN) earns a live Roarable RQD composite score of 24/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $34.36 (+5.01% 1D, market capitalization $1.60B).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 88.7%, operating margin of -60.0%, and free cash flow yield of -9.94%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Per the Roarable profile, UroGen Pharma Ltd. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile identifies the company by its market capitalization of $1.6B. The reported gross margin of 88.7% per the market data section indicates a high-margin revenue base, but the source does not state how that revenue is generated.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), UroGen Pharma Ltd. (URGN) reported $109.8M in annual revenue (up from $90.4M in FY2024, +21.4% YoY) and -$153.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($82.7M revenue, -$102.2M net income) through FY2025, URGN scaled operating cash flow to -$162.4M and free cash flow to -$162.7M, backed by $200.5M in total assets against $122.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 24/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -9.94% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $16.50 – $50.81 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore β€” The only sector context available is the classification of Health Care and the Biotechnology: Pharmaceutical Preparations industry, with a beta of 1.0 per the market data. A prospective investor should note that the absence of mapped links means the graph cannot identify ripple effects from partners, suppliers, or competitors.

  • Key Question #1: Can URGN sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $109.8M and free cash flow of -$162.7M, how will capital allocation balance growth reinvestment against $122.2M in total debt?
  • Key Question #3: How sensitive is URGN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

URGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for UroGen Pharma Ltd. (URGN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to URGN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

URGN Bull vs. Bear Conversation Board β€” What's Your Call at $34.36?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON URGN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on URGN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $40.25 (+23.0%)
πŸ“Œ Pinned Debate

Gross margin of 88.7% and revenue growth from $82.7M to $109.8M show a high-margin product base scaling over FY 2023–FY 2025.

The street is overcomplicating UroGen Pharma Ltd. (URGN). Gross margin of 88.7% and revenue growth from $82.7M to $109.8M show a high-margin product base scaling over FY 2023–FY 2025.. With an RQD score of 24/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $35.34.

SectorRotator πŸ‚ BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (88.7%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $26.50 (-19.0%)
Spot @ $32.72

Negative ROIC of -35%, FCF of -$162.7M in FY 2025, and an Altman Z of 0.2 indicate the business is burning cash in distressed-range fin

Careful chasing URGN at $32.72. Negative ROIC of -35%, FCF of -$162.7M in FY 2025, and an Altman Z of 0.2 indicate the business is burning cash in distressed-range financial condition.. Gross margin is 88.7%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $26.50 on multiple compression.

LIVE TAPE